Gene therapy loses luster as investors eye quicker returns from weight-loss drugs

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward sectors like obesity and cancer, as sales for some of the new treatments fall short.